Our results of intravitreal bevacizumab treatment for choroidal neovascularization secondary to age-related macular degeneration Yaşa baǧli maküla dejenerasyonuna i̇kincil gelişen koroid neovaskülarizasyonlarinda i̇ntravitreal bevacizumab tedavi sonuçlarimiz


Şengül A., ARTUNAY H. Ö., Yüzbaşioǧlu E., Raiser R., Şenel A., Bahçecioǧlu H.

Retina-Vitreus, cilt.18, sa.1, ss.18-22, 2010 (Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 1
  • Basım Tarihi: 2010
  • Dergi Adı: Retina-Vitreus
  • Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.18-22
  • Anahtar Kelimeler: Age related macula degeneration, Intravitreal bevacizumab, Neovascularization
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Purpose: To report efficacy and our results of intravitreal bevacizumab injection for choroidal neovascularization due to age-related macula degeneration (ARMD). Materials and Methods: One hundred four eyes of 79 patients were received 528 injections of 1.25 mg/0.05 mL intravitreal bevacizumab and followed at least one year. Every patient has received injections once a month for 3 consecutive months. Intravitreal reinjections of bevacizumab were administered according to visual acuity (VA) measurements, fundus fluorescein angiography (FFA) and optic coherens tomography (OCT) results. Results: According to mean VA results, 48 eyes (46.2%) had an increase of 5 letters and more. Fifty eyes (48.1%) had no change and 6 eyes (5.7%) had a decrease of 5 letters and more in 3th month. After 12 month follow-up VA results were 43 eyes (41.3%) had an increase of 5 letters and more, 53 eyes (50.9%) had no change and 8 eyes (7.7%) had a decrease of 5 letters and more,. Central macular thickness (CMT) were; in 75 eyes (72.1%) decreased by 100 μm and more, in 23 eyes (22.1%) had no change and in 6 eyes (5.8%) increased by 100 μm and more in 3th month. After 12 month follow-up CMT results were 70 eyes (67.3%) decreased by 100 μm and more, 27 eyes (26.0%) had no change and 7 eyes (6.7%) increased by 100 μm and more. Conclusions: Intravitreal bevacizumab provides significant anatomic and functional improvement compared baseline in choroidal neovascularization due to ARMD.